Cargando…

Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review

Renal cell carcinoma (RCC) associated with anaplastic lymphoma kinase (ALK) gene rearrangements (ALK-RCC) is currently considered an “emerging or provisional” tumor entity by the last World Health Organization classification published in 2016. Although several studies assessing ALK-RCC’s clinical an...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannantuono, Giovanni Maria, Riondino, Silvia, Sganga, Stefano, Roselli, Mario, Torino, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999731/
https://www.ncbi.nlm.nih.gov/pubmed/35409355
http://dx.doi.org/10.3390/ijms23073995
_version_ 1784685259788386304
author Iannantuono, Giovanni Maria
Riondino, Silvia
Sganga, Stefano
Roselli, Mario
Torino, Francesco
author_facet Iannantuono, Giovanni Maria
Riondino, Silvia
Sganga, Stefano
Roselli, Mario
Torino, Francesco
author_sort Iannantuono, Giovanni Maria
collection PubMed
description Renal cell carcinoma (RCC) associated with anaplastic lymphoma kinase (ALK) gene rearrangements (ALK-RCC) is currently considered an “emerging or provisional” tumor entity by the last World Health Organization classification published in 2016. Although several studies assessing ALK-RCC’s clinical and histological characteristics have been published in recent years, only a few publications have evaluated the activity of ALK inhibitors (ALK-i) in this subgroup of patients. Considering the well-recognized efficacy of this evolving class of targeted therapies in other ALK-positive tumors, we conducted a systematic review to evaluate the reported activity of ALK-i in the ALK-RCC subtype. MEDLINE was searched from its inception to 7 January 2022 for case reports and case series on adult metastatic ALK-RCC patients treated with ALK-i whose therapeutic outcomes were available. A virtual cohort of ALK-RCC patients was created. Our results showed a favorable activity of first- and second-generation ALK-i in pretreated ALK-RCC patients in terms of either radiological response or performance status improvement. We hope that the present work will prompt the creation of large, multi-institutional clinical trials to confirm these promising early data.
format Online
Article
Text
id pubmed-8999731
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89997312022-04-12 Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review Iannantuono, Giovanni Maria Riondino, Silvia Sganga, Stefano Roselli, Mario Torino, Francesco Int J Mol Sci Review Renal cell carcinoma (RCC) associated with anaplastic lymphoma kinase (ALK) gene rearrangements (ALK-RCC) is currently considered an “emerging or provisional” tumor entity by the last World Health Organization classification published in 2016. Although several studies assessing ALK-RCC’s clinical and histological characteristics have been published in recent years, only a few publications have evaluated the activity of ALK inhibitors (ALK-i) in this subgroup of patients. Considering the well-recognized efficacy of this evolving class of targeted therapies in other ALK-positive tumors, we conducted a systematic review to evaluate the reported activity of ALK-i in the ALK-RCC subtype. MEDLINE was searched from its inception to 7 January 2022 for case reports and case series on adult metastatic ALK-RCC patients treated with ALK-i whose therapeutic outcomes were available. A virtual cohort of ALK-RCC patients was created. Our results showed a favorable activity of first- and second-generation ALK-i in pretreated ALK-RCC patients in terms of either radiological response or performance status improvement. We hope that the present work will prompt the creation of large, multi-institutional clinical trials to confirm these promising early data. MDPI 2022-04-03 /pmc/articles/PMC8999731/ /pubmed/35409355 http://dx.doi.org/10.3390/ijms23073995 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Iannantuono, Giovanni Maria
Riondino, Silvia
Sganga, Stefano
Roselli, Mario
Torino, Francesco
Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
title Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
title_full Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
title_fullStr Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
title_full_unstemmed Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
title_short Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
title_sort activity of alk inhibitors in renal cancer with alk alterations: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999731/
https://www.ncbi.nlm.nih.gov/pubmed/35409355
http://dx.doi.org/10.3390/ijms23073995
work_keys_str_mv AT iannantuonogiovannimaria activityofalkinhibitorsinrenalcancerwithalkalterationsasystematicreview
AT riondinosilvia activityofalkinhibitorsinrenalcancerwithalkalterationsasystematicreview
AT sgangastefano activityofalkinhibitorsinrenalcancerwithalkalterationsasystematicreview
AT rosellimario activityofalkinhibitorsinrenalcancerwithalkalterationsasystematicreview
AT torinofrancesco activityofalkinhibitorsinrenalcancerwithalkalterationsasystematicreview